Related Experiment Video
Updated: Jun 19, 2026

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms
Ye Ding1, Yuka Harada, Jun Imagawa
1Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
New mutations in AML1/RUNX1 may drive leukemic transformation in myeloproliferative neoplasms (MPNs). These gene alterations were found in patients progressing to leukemia, suggesting a potential role in MPN stem cell leukemogenesis.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Myeloproliferative neoplasms (MPNs) are stem cell disorders with myeloid lineage proliferation.
- Leukemic transformation (LT) in MPNs occurs via unknown mechanisms, potentially influenced by chemotherapy.
- Understanding the molecular drivers of LT is crucial for MPN patient outcomes.
Purpose of the Study:
- To identify gene alterations associated with leukemic transformation in MPNs.
- To investigate the leukemogenic potential of identified gene mutations in MPN stem cells.
Main Methods:
- Gene alteration analysis in patients with MPNs progressing from chronic phase (CP) to leukemia.
- Transduction of AML1/RUNX1 mutants into CD34(+) cells from MPN patients in CP.
- Assessment of myeloid cell proliferation, self-renewal, and progenitor capacity post-transduction.
Main Results:
- AML1/RUNX1 mutations were detected in 5 of 18 patients at leukemic transformation (LT), but not in the chronic phase (CP).
- Transduction of the AML1D171N mutant into MPN stem cells induced immature myeloid cell proliferation.
- The AML1D171N mutant enhanced self-renewal and proliferation of primitive progenitor cells.
Conclusions:
- AML1/RUNX1 point mutations demonstrate leukemogenic potential in MPN stem cells.
- These mutations may play a significant role in promoting leukemic transformation in myeloproliferative neoplasms.
- Targeting AML1/RUNX1 mutations could be a therapeutic strategy for preventing MPN progression.
Related Concept Videos
Abnormal Proliferation
Non-LTR Retrotransposons
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

